ACTRIMS 2022 | Developments in biomarkers for MS susceptibility and prodrome

Raphael Schneider, MD, PhD, FRCPC, CIP, St. Michael’s Hospital, Toronto, Canada, outlines the potential use of neurofilament light (NfL) and glial fibrillary acidic protein (GFAP) as biomarkers for susceptibility and onset of multiple sclerosis (MS). Dr Schneider explains that testing for an increase in NfL or GFAP, in the plasma or serum of a patient with radiologically isolated syndrome (RIS), is easier than using multiple biomarkers and complex technology to analyze the immune cell compartment. This interview took place at the ACTRIMS Forum 2022 in West Palm Beach, Florida.